Saishunkan Pharmaceutical

Saishunkan Pharmaceutical

Founded in 1959 by Masaaki Nishikawa, Saishunkan Pharmaceutical began as a developer of pharmaceutical products, health supplements, and cosmetics. The company remains under family control: Masaaki Nishikawa serves as Representative Director and President, while Michiko Nishikawa chairs the broader Nishikawa Group. The underlying wealth stems from decades of direct-to-consumer supplement and skincare sales in Japan, which generated the capital now directed into a diverse investment portfolio. Saishunkan's investment strategy spans venture investing, real estate, and renewable energy. The firm explicitly targets early-stage opportunities. Its direct holdings include a senior-housing portfolio under the Hospitalment brand, with properties in Tokyo, Kumamoto, Fukuoka, and Hyogo. Through the Sakurajyuji Group — led by Tomoki Nishikawa — the family controls Sakurajyuji Hospital in Kumamoto and a medical square in Fukuoka. In renewable energy, Saishunkan operates a solar power plant in its home prefecture of Kumamoto. Strategic partnerships extend the footprint: the ReSUNOKO Square mixed-use project in Fukuoka was jointly developed with JR Kyushu Group, and a collaboration with CHC Healthcare Group gives the firm a vehicle for entering Taiwan's long-term care market. Beyond the core operating company, the family's holdings are structured across several vehicles. The Nishikawa Group umbrella includes Saishunkan Pharmaceutical, the Sakurajyuji Group, and the Hospitalment senior-living portfolio. A Tokyo office at Azabudai Hills Mori JP Tower places the group within Japan's premier business district. The Sakurajyuji Group's headquarters in that tower signal an ambition to engage with institutional partners and property-level operators far beyond the Kyushu home base. In September 2023, Saishunkan opened a direct-to-consumer flagship experience center in Kumamoto, reinforcing its brand-driven consumer business while the investment arm continues to deploy off the same balance sheet. What distinguishes Saishunkan is its structure as a family-controlled operating company that allocates directly alongside its core consumer business. The investment portfolio is blended with operating assets — a hospital, senior housing, a solar plant — and there is no external fund structure or LP capital involved. This hybrid model allows the Nishikawa family to use cash flows from supplements and cosmetics to fund long-duration real assets and venture bets without the pacing pressure of institutional funds. The group's philanthropic arm, Nishikawa Group Philanthropy, formalizes a social commitment that runs parallel to the commercial activities, though governance and asset separation between the commercial entities and the foundation are not publicly detailed.